Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/16/2025 | $12.00 | Sector Outperform | Scotiabank |
| 3/14/2025 | Overweight | Cantor Fitzgerald | |
| 7/10/2023 | $22.00 | Buy | Guggenheim |
| 11/8/2021 | $32.00 → $34.00 | Outperform | Oppenheimer |
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies. "We are delighted to welcome Dr. Nicacio to the Protara team," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "As a proven leader with deep expertise spanning all stages of drug development, his guida
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that two presentations and a panel discussion highlighting the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured at the upcoming American Urological Association (AUA) 2025 Annual Meeting taking place from April 26, 2025 to April 29, 2025 in Las Vegas. A copy of the abstract for the ADVANCED-2 interim analysis is now available on the AUA website. Updated safety and efficacy data, including data from
Data to be featured during oral presentation at the American Society for Parenteral and Enteral Nutrition 2025 Nutrition Science & Practice ConferenceDosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025 NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from THRIVE-1, a prospective, observational study evaluating the prevalence of choline deficiency and liver injury in patients dependent on parenteral support (PS), will be featured
SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
S-8 - Protara Therapeutics, Inc. (0001359931) (Filer)
10-K - Protara Therapeutics, Inc. (0001359931) (Filer)
NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer. Dr. Nicacio brings to Protara nearly 20 years of broad oncology, drug development, regulatory and commercial experience across leading biopharmaceutical and health technology companies. "We are delighted to welcome Dr. Nicacio to the Protara team," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "As a proven leader with deep expertise spanning all stages of drug development, his guida
- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021 Expected to Fund Operations into Mid-2024 - NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. "Following a productive 2021, we are well poised to advance our pipeline in 2022, in particular, we are excited to have commenced our Phase 1 study of TARA-002 in non-muscle invasive b
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer. "We are thr
TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposuresFavorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse eventsCompany to host conference call and webcast today at
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, December 5, 2024, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology on December 5, 2024, at 1:15 p.m. CT. The live call can be accessed by registering as a participant here. Upo
Scotiabank initiated coverage of Protara Therapeutics with a rating of Sector Outperform and set a new price target of $12.00
Cantor Fitzgerald initiated coverage of Protara Therapeutics with a rating of Overweight
Guggenheim resumed coverage of Protara Therapeutics with a rating of Buy and set a new price target of $22.00
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
3 - Protara Therapeutics, Inc. (0001359931) (Issuer)
4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)